Upstream Biotechnology, Inc. filed a Form D with the Securities and Exchange Commission on 2025-09-17.
Upstream Biotechnology, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 17, 2025. The filing reports $625K sold. Its industry group is Other Technology. It names George Greene (Executive Officer, Director), Xinnian Dong (Director), Xiao-fang Wang (Dr. Wang resigned as a director in connection with the Offering.) (SEC Form D, September 17, 2025).
Is this your company?
Sell to companies like Upstream Biotechnology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-17 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Upstream Biotechnology, Inc.
Free to see. No signup.
More on the people and the money behind Upstream Biotechnology, Inc., from the filings we hold.
Other Technology raises by companies based in North Carolina, filed in September 2025, largest first.
Get an email when Upstream Biotechnology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Upstream Biotechnology, Inc. raises, hires or launches. No email unless you switch it on.
Watch Upstream Biotechnology, Inc. →Get the full cited report on Upstream Biotechnology, Inc.
What the filing shows about Upstream Biotechnology, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Upstream Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Upstream Biotechnology, Inc.'s address as 701 W. Main Street, Suite 200, Durham, NC 27701.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Upstream Biotechnology, Inc. See pricing
Upstream Biotechnology, Inc. is a registered filer with the SEC (CIK 2086249) and has filed since 2025-09-17. 1 filing is on record, the latest on 2025-09-17.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Upstream Biotechnology, Inc.'s Form D of 2025-09-17 names George Greene, Xinnian Dong, Xiao-fang Wang and 1 more as its officers, directors or promoters.
Its new offerings report $625K sold across 1 offering, as its own filings state.
Trailing twelve months. 3844 filings in Other Technology, totalled by week.
Other than the payment of salaries and other compensation and benefits and reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering.
George Greene is named as Executive Officer and Director on the Form D that Upstream Biotechnology, Inc. filed with the SEC on 17 September 2025, one of 4 people that filing names.
Xinnian Dong is named as Director on the Form D that Upstream Biotechnology, Inc. filed with the SEC on 17 September 2025, one of 4 people that filing names.
On the filing as: Director.
Xiao-fang Wang is named as Dr. Wang resigned as a director in connection with the Offering. on the Form D that Upstream Biotechnology, Inc. filed with the SEC on 17 September 2025, one of 4 people that filing names.
On the filing as: Director.
Karen LeVert is named as Ms. LeVert was elected a director in connection with the Offering. on the Form D that Upstream Biotechnology, Inc. filed with the SEC on 17 September 2025, one of 4 people that filing names.
4 people named on the filing — 1 holding an executive role and 3 as directors only.
Named as of the 2025-09-17 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Upstream Biotechnology, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Upstream Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Upstream Biotechnology, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Upstream Biotechnology, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Upstream Biotechnology, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Upstream Biotechnology, Inc.. With no account yet, you sign up free and land on the result.
On these lists: AI and software raises in Raleigh-Durham
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/upstream-biotechnology-inc-form-d-25000001